DOCSLIB.ORG

Outline of Lecture 3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Outline of Lecture 3 Outline of Lecture 3 C2006/F2402 '14 -- Outline Of Lecture #3 -- Last update 01/29/2014 10:10 AM -- Two clarifications were added after the live lectures. They are in blue. (c) 2014 Deborah Mowshowitz, Department of Biological Sciences, Columbia University, New York NY Handouts*: 3A -- Freeze Fracture; Types of Membrane Proteins 3B -- RBC Membrane, RBC -- Role of Anion Exchanger 3C -- ECM (Extracellular Matrix) Pictures (Power Point Slides) shown at the start of the lecture are on Courseworks for registered students. The main menu page includes a link to the web-sites page. This page has links to web sites that you may find interesting and/or helpful. The web sites contain animations, explanations, pictures etc. that are relevant to this course. (The list is not complete; I'll add to it as we go.) I will add specific links in the lectures, but you may want to explore some of the sites on your own. Please let me know if any of the web sites are useful, and/or if you find any other good ones. I. Introduction to Membrane Structure A. The Big Question: What does the structure seen in the EM represent? For possibilities, see Becker fig. 7-3. For an EM picture, see PPt slides, slide #1 or Becker, fig. 7-4. B. Lipid part 1. Amphipathic nature of lipids -- See Sadava fig. 6.2 -- there are multiple different "two headed" lipids - - each type has a different structure, but each has a hydrophobic end and hydrophilic end. 2. Amphipathic Lipids form a bilayer. C. Protein part -- where are the proteins (relative to the lipid)? Is it a "unit membrane" or a "fluid mosaic?" For "unit membrane" See Becker fig. 7-4 or PPT slide #1 for EM picture; for fluid mosaic model see Becker fig. 7-5 or Sadava fig. 6.1. 1. Use of freeze fracture procedure a. E vs P faces of bilayer = surfaces you see if you crack bilayer open = inside of bilayer (1). E face = inside of the monolayer that is closer to extracellular space (outside of cell) (2). P face = inside of the monolayer that is closer to protoplasm (inside of cell) b. What do you see on inside? See Becker fig. 7-16 & 7-17 or Sadava fig. 6.4 or top panel on handout 3A. (1) Inside is not smooth -- shows proteins go through bilayer (implies "mosaic" model not unit membrane) (2). More bumps (proteins) on P face than E face -- shows more proteins anchored on cytoplasmic (protoplasmic) side. 2. Freeze fracture vs Freeze etch file:///C|/Users/dbm2/Documents/COURSES/C2006/current-lectures14/lect3.14.html[1/29/2014 10:18:17 AM] Outline of Lecture 3 a. Freeze fracture = crack frozen sample open, examine in EM; b. Freeze etch = crack open, let some water sublime off to expose deeper layers, then look in EM. For some sample pictures, see Becker figs. 15-15 (15-16), 15-18 (15-19), 15-24 (15-25), & 16-1. D. Fluid mosaic model -- overview of current idea of how proteins and lipids are arranged. See Becker fig. 7-5 (or 7-3) or Sadava fig. 6.1. Also handout 3A, middle of top panel. II. Fluid Mosaic Model of Membrane Structure A. Fluid Part = Lipid bilayer 1. Formation of Bilayer -- All amphipathic lipids form bilayers. In cell, virtually all lipids are inserted from one side of the bilayer of the ER (side facing the cytoplasm). How do lipids get to the other half of the bilayer? 2. Lateral diffusion vs. flip-flop of lipids. See Becker 7-10 & 7-11. lateral diffusion = movement within plane of membrane -- fast (secs). Animation of lateral diffusion. Also see Sadava fig. 6.5 or Becker fig. 7-28 & 7-29. flip-flop = movement from one side of bilayer to the other -- slow (hrs) w/o enzymes. Enzymes (flipases = phospholipid translocators) are needed to speed flip-flop. (More details when we get to transport.) 3. Two sides of a bilayer often have a different lipid composition. (One side = 1/2 of bilayer = a leaflet.) B. Mosaic Part = Protein. Types of Membrane Proteins -- what do you get if you take a membrane apart? See handout 3A, bottom panel. 1. Peripheral membrane proteins vs. integral membrane proteins Type of Protein Removed Membrane Alt. terminology Location/Attachment of Protein From Membrane By Protein On one 1 side of bilayer; non covalently attached Peripheral Extrinsic salt, pH changes to lipid Goes through bilayer* or Covalently attached to Integral Intrinsic disrupting lipid bilayer lipid on one side (Lipid-anchored)** * A small number of integral proteins do not go all the way through the membrane; they will be largely ignored in this course. For examples see Becker fig. 7-19 (first protein on left) or Sadava fig. 6.1 -- last protein on right. **Note that lipid-anchored proteins can be considered a type of integral protein or a separate category. See Becker fig. 7-19. 2. Transmembrane proteins of plasma membrane (See Sadava fig. 6.3 and/or Becker fig. 7-19 & 7-21) a. Single pass vs multipass b. Domains -- intracellular, extracellular, transmembrane. Note: For a multipass protein, each individual section or stretch of polypeptide (transmembrane, extracellular, or intracellular) is file:///C|/Users/dbm2/Documents/COURSES/C2006/current-lectures14/lect3.14.html[1/29/2014 10:18:17 AM] Outline of Lecture 3 usually considered a separate domain. See answer to problem 1-20. All the extracellular or all the intracellular domains may cluster together, but the term 'domain' is not usually used for the entire extracellular (or intracellular) part of the protein. c. Location of carbohydrates -- all in extracellular domain (all added inside EMS) d. Anchorage -- Some proteins are anchored to cytoskeleton; some float in lipid bilayer. e. Types & Functions -- All bridge the membrane but function differs. Can be: (1). Transport proteins -- Allow transport of small molecules in and out of cells. ('pumps' or 'doors'.) (2). Receptors -- Trap (bind) molecules on outside. Then receptor can facilitate: (a). Transport -- By invagination of membrane. Trapped large molecules are transported into cell in a vesicle (by RME -- receptor mediated endocytosis). Example: Receptor for LDL (low density lipoprotein -- a carrier for cholesterol). (b). Transmission of signals -- relays signals to inside of cell from trapped molecule on outside of cell. Example: Receptor for Acetyl Choline (a neurotransmitter). (c). Both -- can facilitate both transmission of signal and internalization of signal molecule. Typical Examples: Receptors for growth factors. Specific example: Receptor for EGF. (EGF = Epidermal Growth Factor) (3). Connectors -- physically connect cytoskeleton (inside of cell) to materials on outside of cell (ECM = extracellular matrix) or to next cell. Example: cadherins (connect cells) & integrins (connect cells and ECM). More on this next time. (4). More than one of the above -- some transmembrane proteins act in more than one capacity. Examples: Integrins (connectors & act in signaling). III. The Red Blood Cell (RBC) Membrane -- The best studied example of a Membrane. For pictures of RBC see the PPt slides for lecture #3. A. Why RBC's 1. Easy to get 2. No internal membranes -- all organelles lost during maturation of human RBC -- see Becker fig. 7-20 (a). Only membrane = plasma membrane. 3. Can make 'ghosts' = resealed plasma membranes. Can be resealed (or broken and reformed into vesicles) in either orientation -- "right" or "wrong" side out. See PPt slides, slide #4. B. RBC membrane proteins -- Structure & Function. See Becker fig. 7-20 (b) & 15-19 (15-20). (Handout 3B -- top) 1. Peripheral proteins -- spectrin, ankyrin, (band 4.1), actin. Comprise peripheral cytoskeleton, which supports membrane. All cells are thought to have a similar structure under the plasma membrane. 2. Intrinsic proteins -- Two basic kinds -- single pass & multipass. a. Example of RBC single pass -- glycophorin -- function of protein not known. file:///C|/Users/dbm2/Documents/COURSES/C2006/current-lectures14/lect3.14.html[1/29/2014 10:18:17 AM] Outline of Lecture 3 (1). Has large amount of (-) charged modified carbohydrate -- sialic acid. Possible functions: (a). Neg. charge may cause RBC to repel each other and prevent clumping of RBC. (b). Loss of terminal sugars may occur with age and trigger destruction of "old" RBC. (2). Glycophorins make up a gene family; variations in glycophorin A are responsible for MN blood type differences. Variations in glycophorin C are correlated with resistance to malaria. b. Example of RBC Multipass -- band 3/anion exchanger -- Catalyzes reversible exchange - - of the anions HCO3 (bicarb) and Cl between RBC and plasma. Exchange allows max. transport of CO2 in blood (as bicarb in solution). See Sadava fig. 49.14 or Becker 8-3. (1). Why is transport of CO2 an issue? Tissues carry out oxidative metabolism and generate lots of CO2 . The CO2 diffuses out of the cells into the blood. However the solubility of CO2 in plasma (cell-free liquid portion of the blood) is limited. (2). Basic idea: Bicarb is much more soluble in plasma than CO2, so lots of bicarb (but not much CO2) can be carried in the blood. Therefore need to covert CO2 to bicarb when want to carry CO2 in blood; need to do reverse to eliminate the CO2 (in lungs). (3). Role of Carbonic anhydrase: Conversion of CO2 to bicarb (& vice versa) can only occur inside RBC, where the enzyme carbonic anhydrase is. (See handout 3B, middle panel.) Carbonic anhydrase catalyzes: - + CO2 + H2O ↔ HCO3 + H (4). Role of exchanger: Gases can pass through membranes by diffusion -- CO2 can exit or enter RBC as needed. However bicarb cannot pass through membranes. You need the anion exchanger to get bicarb in and out of RBC. (5). Physiological Function of Exchanger (a). Where CO2 is high, as in tissues, CO2 diffuses into RBC and is converted to bicarb inside the RBC.
Load more

Recommended publications
  • Distribution and Clinical Significance of Heparan Sulfate Proteoglycans in Ovarian Cancer
    5178 Vol. 10, 5178–5186, August 1, 2004 Clinical Cancer Research Distribution and Clinical Significance of Heparan Sulfate Proteoglycans in Ovarian Cancer E. June Davies,1 Fiona H. Blackhall,1 decan-1 and glypican-1 were poor prognostic factors for Jonathan H. Shanks,2 Guido David,3 survival in univariate analysis. Alan T. McGown,4 Ric Swindell,5 Conclusion: We report for the first time distinct pat- 6 7 terns of expression of cell surface and extracellular matrix Richard J. Slade, Pierre Martin-Hirsch, heparan sulfate proteoglycans in normal ovary compared 1 1 John T. Gallagher, and Gordon C. Jayson with ovarian tumors. These data reinforce the role of the 1Cancer Research UK and University of Manchester Department of tumor stroma in ovarian adenocarcinoma and suggest that Medical Oncology, Paterson Institute for Cancer Research, stromal induction of syndecan-1 contributes to the patho- Manchester, England; 2Department of Histopathology, Christie Hospital NHS Trust, Manchester, England; 3Department of Medicine, genesis of this malignancy. University of Leuven, Leuven, Belgium.; 4Cancer Research UK Department of Experimental Pharmacology, Paterson Institute for Cancer Research, Manchester, England; 5Department of Medical INTRODUCTION Statistics, Christie Hospital NHS Trust, Manchester, England; The heparan sulfate proteoglycans (HSPGs) play diverse 6Department of Obstetrics and Gynaecology, Hope Hospital, Salford, Manchester, England; 7Department of Gynaecological Oncology, St. roles in tumor biology by mediating adhesion and migration
    [Show full text]
  • Three Is a Crowd
    TREPAR 1600 No. of Pages 12 Review Three Rosetting[403_TD$IF] in Plasmodium falciparum Xue Yan Yam,1,3 Makhtar Niang,2,3 Kripa Gopal Madnani,1,3 and Peter R. Preiser1,* The intracellular malaria parasites extensively modify host erythrocytes to allow Trends nutrient uptake, ensure homeostasis, and evade the host’s immune response. Rosetting, the binding of uninfected To achieve this, the parasite exports several proteins to the erythrocyte surface. RBCs to a parasite-infected RBC In Plasmodium falciparum, the parasite responsible for the most severe form of (iRBC), has been directly linked to human malaria, three major variant surface antigen families – PfEMP1, STE- the severity of clinical disease. VOR, and RIFIN – have been implicated in contributing to immune evasion, Three parasite protein families, parasite sequestration, and parasite-mediated rosetting of uninfected eryth- PfEMP1, STEVOR, and RIFIN, mediate rosetting in Plasmodium falciparum. rocytes. Sequestration and rosetting have been linked to parasite-mediated pathology, making the variant surface antigens of P. falciparum major virulence Sequential timing of surface expres- factors. Here we review our current understanding of rosetting mechanism, sion of PfEMP1, RIFIN, and STEVOR fi on iRBC suggests that the parasite has recent ndings of STEVOR, RIFIN-mediated rosetting, and their implication on developed three different rosette for- the severity and pathology of the disease. mation mechanisms, implicating a cri- tical function for parasite survival. Plasmodium Variant Surface Antigens of Parasites: A Role in Rosetting PfEMP1 mediates rosetting through Plasmodium parasites have a complex life cycle involving a mosquito vector and a mammalian CR1, heparan sulfate, and blood group host.
    [Show full text]
  • Aggrecan (A1960)
    Aggrecan from bovine articular cartilage Catalog Number A1960 Storage Temperature –20 °C Product Description References Aggrecan is the major structural proteoglycan found in 1. Hardingham, T.E., and Muir, H., Biochim. Biophys. the extracellular matrix of cartilage. It has a molecular Acta, 279, 401-405 (1972). mass >2,500 kDa. The core protein (210–250 kDa) has 2. Hedlund, H., et al., Association of the aggrecan 100–150 glycosaminoglycan (GAG) chains attached to keratan sulfate-rich region with collagen in bovine it. The majority of the GAG chains are chondroitin/ articular cartilage. J. Biol. Chem., 274, 5777-5781 dermatan sulfate with the remainder being keratan (1999). sulfate. This structural molecule produces a rigid, 3. Cao, L., and Yang, B.B., Chondrocyte apoptosis reversibly deformable gel that resists compression. It induced by aggrecan G1 domain as a result of combines with hyaluronic acid to form very large decreased cell adhesion. Exp. Cell Res., 246, 527- macromolecular complexes. Addition of small amounts 537 (1999). (0.1–2% w/w) of hyaluronic acid to a solution of 4. Bolton, M.C., et al., Age-related changes in the aggrecan (2 mg/ml) results in the formation of a synthesis of link protein and aggrecan in human complex with an increased hydrodynamic volume and articular cartilage: implications for aggregate in a significant increase (30–40%) in the relative stability. Biochem. J., 337, 77-82 (1999). viscosity of the solution. 5. Arner, E.C., et al., Generation and Characterization of Aggrecanase. A soluble, cartilage-derived Aggrecan is a critical component for cartilage structure aggrecan-degrading activity.
    [Show full text]
  • Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis
    International Journal of Molecular Sciences Review Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis Aldona Kasprzak 1,* and Agnieszka Adamek 2 1 Department of Histology and Embryology, Poznan University of Medical Sciences, Swiecicki Street 6, 60-781 Pozna´n,Poland 2 Department of Infectious Diseases, Hepatology and Acquired Immunodeficiencies, University of Medical Sciences, Szwajcarska Street 3, 61-285 Pozna´n,Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-61-8546441; Fax: +48-61-8546440 Received: 25 February 2019; Accepted: 10 March 2019; Published: 14 March 2019 Abstract: Mucins are large O-glycoproteins with high carbohydrate content and marked diversity in both the apoprotein and the oligosaccharide moieties. All three mucin types, trans-membrane (e.g., MUC1, MUC4, MUC16), secreted (gel-forming) (e.g., MUC2, MUC5AC, MUC6) and soluble (non-gel-forming) (e.g., MUC7, MUC8, MUC9, MUC20), are critical in maintaining cellular functions, particularly those of epithelial surfaces. Their aberrant expression and/or altered subcellular localization is a factor of tumour growth and apoptosis induced by oxidative stress and several anti-cancer agents. Abnormal expression of mucins was observed in human carcinomas that arise in various gastrointestinal organs. It was widely believed that hepatocellular carcinoma (HCC) does not produce mucins, whereas cholangiocarcinoma (CC) or combined HCC-CC may produce these glycoproteins. However, a growing number of reports shows that mucins can be produced by HCC cells that do not exhibit or are yet to undergo, morphological differentiation to biliary phenotypes. Evaluation of mucin expression levels in precursors and early lesions of CC, as well as other types of primary liver cancer (PLC), conducted in in vitro and in vivo models, allowed to discover the mechanisms of their action, as well as their participation in the most important signalling pathways of liver cystogenesis and carcinogenesis.
    [Show full text]
  • MUC16 (CA125): Tumor Biomarker to Cancer Therapy, a Work in Progress
    Felder et al. Molecular Cancer 2014, 13:129 http://www.molecular-cancer.com/content/13/1/129 REVIEW Open Access MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress Mildred Felder1†, Arvinder Kapur1†, Jesus Gonzalez-Bosquet2, Sachi Horibata1, Joseph Heintz3, Ralph Albrecht3, Lucas Fass1, Justanjyot Kaur1, Kevin Hu4, Hadi Shojaei1, Rebecca J Whelan4* and Manish S Patankar1* Abstract Over three decades have passed since the first report on the expression of CA125 by ovarian tumors. Since that time our understanding of ovarian cancer biology has changed significantly to the point that these tumors are now classified based on molecular phenotype and not purely on histological attributes. However, CA125 continues to be, with the recent exception of HE4, the only clinically reliable diagnostic marker for ovarian cancer. Many large-scale clinical trials have been conducted or are underway to determine potential use of serum CA125 levels as a screening modality or to distinguish between benign and malignant pelvic masses. CA125 is a peptide epitope of a3–5 million Da mucin, MUC16. Here we provide an in-depth review of the literature to highlight the importance of CA125 as a prognostic and diagnostic marker for ovarian cancer. We focus on the increasing body of literature describing the biological role of MUC16 in the progression and metastasis of ovarian tumors. Finally, we consider previous and on-going efforts to develop therapeutic approaches to eradicate ovarian tumors by targeting MUC16. Even though CA125 is a crucial marker for ovarian cancer, the exact structural definition of this antigen continues to be elusive. The importance of MUC16/CA125 in the diagnosis, progression and therapy of ovarian cancer warrants the need for in-depth research on the biochemistry and biology of this mucin.
    [Show full text]
  • The Future of B-Cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus
    pISSN: 2093-940X, eISSN: 2233-4718 Journal of Rheumatic Diseases Vol. 24, No. 2, April, 2017 https://doi.org/10.4078/jrd.2017.24.2.65 Review Article The Future of B-cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus William Stohl Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA To review B-cell activating factor (BAFF)-antagonist therapy in systemic lupus erythematosus (SLE), literature was searched us- ing the search words and phrases, “BAFF”, “B lymphocyte stimulator (BLyS)”, “a proliferation-inducing ligand (APRIL)”, “B-cell maturation antigen (BCMA)”, “transmembrane activator and calcium-modulating and cyclophilin ligand interactor (TACI)”, “BLyS receptor 3 (BR3)”, “belimumab”, “atacicept”, “blisibimod”, “tabalumab”, and “lupus clinical trial”. In addition, papers from the author’s personal library were searched. BAFF-antagonist therapy in SLE has a checkered past, with four late-stage clin- ical trials meeting their primary endpoints and four failing to do so. Additional late-stage clinical trials are enrolling subjects to address some of the remaining unresolved questions, and novel approaches are proposed to improve results. The BAFF-centric pathway is a proven therapeutic target in SLE. As the only pathway in the past 50+ years to have yielded an United States Food and Drug Administration-approved drug for SLE, it occupies a unique place in the armamentarium of the practicing rheumatologist. The challenges facing clinicians and investigators are how to better tweak the BAFF-centric pathway and im- prove on the successes realized. (J Rheum Dis 2017;24:65-73) Key Words.
    [Show full text]
  • T Cell Reactivity + Autoantibodies and CD4 Therapy Is Mediated By
    Suppression of Proteoglycan-Induced Arthritis by Anti-CD20 B Cell Depletion Therapy Is Mediated by Reduction in Autoantibodies and CD4 + T Cell Reactivity This information is current as of September 27, 2021. Keith Hamel, Paul Doodes, Yanxia Cao, Yumei Wang, Jeffrey Martinson, Robert Dunn, Marilyn R. Kehry, Balint Farkas and Alison Finnegan J Immunol 2008; 180:4994-5003; ; doi: 10.4049/jimmunol.180.7.4994 Downloaded from http://www.jimmunol.org/content/180/7/4994 References This article cites 48 articles, 20 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/180/7/4994.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Suppression of Proteoglycan-Induced Arthritis by Anti-CD20 B Cell Depletion Therapy Is Mediated by Reduction in Autoantibodies and CD4؉ T Cell Reactivity1 Keith Hamel,* Paul Doodes,* Yanxia Cao,† Yumei Wang,† Jeffrey Martinson,* Robert Dunn,§ Marilyn R.
    [Show full text]
  • Sulfated Glycoaminoglycans and Proteoglycan Syndecan-4 Are Involved in Membrane Fixation of LL-37 and Its Pro-Migratory Effect I
    Sulfated Glycoaminoglycans and Proteoglycan Syndecan-4 Are Involved in Membrane Fixation of LL-37 and Its Pro-Migratory Effect in Breast Cancer Cells Chahrazed Habes, Günther Weber, Caroline Goupille To cite this version: Chahrazed Habes, Günther Weber, Caroline Goupille. Sulfated Glycoaminoglycans and Proteoglycan Syndecan-4 Are Involved in Membrane Fixation of LL-37 and Its Pro-Migratory Effect in Breast Cancer Cells. Biomolecules, MDPI, 2019, 9 (9), pp.481. 10.3390/biom9090481. hal-02958728 HAL Id: hal-02958728 https://hal.archives-ouvertes.fr/hal-02958728 Submitted on 6 Oct 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. biomolecules Article Sulfated Glycoaminoglycans and Proteoglycan Syndecan-4 Are Involved in Membrane Fixation of LL-37 and Its Pro-Migratory Effect in Breast Cancer Cells Chahrazed Habes 1, Günther Weber 1,* and Caroline Goupille 1,2 1 INSERM, Université de Tours, UMR 1069 Nutrition, Growth and Cancer, 37032 Tours, France; [email protected] (C.H.); [email protected] (C.G.) 2 CHRU de Tours, Hôpital Bretonneau, 37032 Tours, France * Correspondence: [email protected]; Tel.: +33-247-366-294 Received: 27 July 2019; Accepted: 10 September 2019; Published: 12 September 2019 Abstract: Initially characterized by its antimicrobial activities, LL-37 has also been shown to significantly contribute to tumor development.
    [Show full text]
  • B Cell–Specific Expression of Inducible Costimulator Ligand Is Necessary for the Induction of Arthritis in Mice
    ARTHRITIS & RHEUMATOLOGY Vol. 66, No. 1, January 2014, pp 60–67 DOI 10.1002/art.38207 © 2014, American College of Rheumatology B Cell–Specific Expression of Inducible Costimulator Ligand Is Necessary for the Induction of Arthritis in Mice Keith M. Hamel,1 Yanxia Cao,2 Susan A. Olalekan,2 and Alison Finnegan2 Objective. Inducible costimulator (ICOS)–ICOSL actions may be an effective strategy for the treatment of interactions are necessary for activation of Teff cells rheumatoid arthritis. and follicular helper T (Tfh) cells. ICOSL is expressed on B cells, macrophages, and dendritic cells and can be In rheumatoid arthritis (RA), autoreactive T cells induced on nonhematopoietic cells. The aim of this are implicated in the disease process, based on genetic study was to determine whether expression of ICOSL on linkage between disease susceptibility and HLA alleles B cells is necessary for the development of proteoglycan and evidence derived from experimental models of (PG)–induced arthritis (PGIA). arthritis (1). T cell activation requires T cell receptor Methods. PGIA was initiated by immunizing wild- ligation in addition to secondary and tertiary signals type and ICOSL-deficient (ICOSL؊/؊) or B cell–specific provided by costimulator molecules and cytokines. The ICOSL؊/؊ chimeric BALB/c mice with human PG in interaction between CD28 on T cells and CD80/CD86 adjuvant. The onset and severity of arthritis were mon- on antigen-presenting cells (APCs) is the most promi- itored over time. CD4؉ T cell proliferation and CD4؉ nent of these costimulatory interactions (2). Successful T cell cytokine production were measured in vitro after therapeutic intervention with the CD28 costimulatory the cells were restimulated with PG.
    [Show full text]
  • The Structure and Function of Cartilage Proteoglycans
    PJEuropean Roughley Cells and Materials Vol. 12. 2006 (pages 92-101) DOI: 10.22203/eCM.v012a11 Cartilage ISSN proteoglycans 1473-2262 THE STRUCTURE AND FUNCTION OF CARTILAGE PROTEOGLYCANS P.J. Roughley* Genetics Unit, Shriners Hospital for Children and Department of Surgery, McGill University, Montreal, Quebec, Canada Abstract Introduction Cartilage contains a variety of proteoglycans that are Cartilagenous tissues are present throughout the body at essential for its normal function. These include aggrecan, numerous sites and are classified histologically as being decorin, biglycan, fibromodulin and lumican. Each hyaline, elastic or fibrocartilagenous in nature, depending proteoglycan serves several functions that are determined on their molecular composition. Elastic cartilage is by both its core protein and its glycosaminoglycan chains. associated with the ear and the larynx, whereas This review discusses the structure/function relationships fibrocartilage is associated with the menisci of the knee of the cartilage proteoglycans, and the manner in which and the intervertebral discs. Hyaline cartilage is the perturbations in proteoglycan structure or abundance can predominant form of cartilage, and is most commonly adversely affect tissue function. associated with the skeletal system, where it forms the anlage for many bones in the embryo, the growth plate Key Words: Proteoglycan, aggrecan, link protein, via which many bones increase their size during juvenile hyaluronan, decorin, biglycan, fibromodulin, lumican, development, and the bearing surface upon which bones cartilage. articulate in movable joints. It is not clear whether articular cartilage can be defined as a distinct tissue in the juvenile, as it forms a continuum with the hyaline cartilage of the central epiphysis, which is destined to be resorbed.
    [Show full text]
  • Activins and Inhibins: Roles in Development, Physiology, and Disease
    Downloaded from http://cshperspectives.cshlp.org/ on October 5, 2021 - Published by Cold Spring Harbor Laboratory Press Activins and Inhibins: Roles in Development, Physiology, and Disease Maria Namwanje1 and Chester W. Brown1,2,3 1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030 2Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030 3Texas Children’s Hospital, Houston, Texas 77030 Correspondence: [email protected] Since their original discovery as regulators of follicle-stimulating hormone (FSH) secretion and erythropoiesis, the TGF-b family members activin and inhibin have been shown to participate in a variety of biological processes, from the earliest stages of embryonic devel- opment to highly specialized functions in terminally differentiated cells and tissues. Herein, we present the history, structures, signaling mechanisms, regulation, and biological process- es in which activins and inhibins participate, including several recently discovered biolog- ical activities and functional antagonists. The potential therapeutic relevance of these advances is also discussed. INTRODUCTION, HISTORY AND which the activins and inhibins participate, rep- NOMENCLATURE resenting some of the most fascinating aspects of TGF-b family biology. We will also incorporate he activins and inhibins are among the 33 new biological activities that have been recently Tmembers of the TGF-b family and were first discovered, the potential clinical relevance of described as regulators of follicle-stimulating
    [Show full text]
  • Studies of the Articular Cartilage Proteoglycan Aggrecan in Health and Osteoarthritis
    Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. G Rizkalla, … , E Bogoch, A R Poole J Clin Invest. 1992;90(6):2268-2277. https://doi.org/10.1172/JCI116113. Research Article Changes in the structure of the proteoglycan aggrecan (PG) of articular cartilage were determined immunochemically by RIA and gel chromatography and related to cartilage degeneration documented histologically by the Mankin grading system. Monoclonal antibodies to glycosaminoglycan epitopes were used. In all cartilages, three chondroitin sulfate (CS)- rich populations of large size were observed in addition to a smaller keratan sulfate (KS)-rich population. In grades 7-13 OA cartilages (phase II), molecules were significantly larger than the equivalent molecules of grades 2-6 (phase I). CS chain lengths remained unchanged. In most OA cartilages, a CS epitope 846 was elevated in content, this being most marked in phase II (mean: fivefold). Loss of uronic acid, KS, and hyaluronic acid were only pronounced in phase II OA because of variations in normal contents. Aggregation of PG was unchanged (50-60%) or reduced in OA cartilages, but molecules bearing epitope 846 exhibited almost complete aggregation in normal cartilages. This study provides evidence for the capacity of OA cartilage to synthesize new aggrecan molecules to replace those damaged and lost by disease- related changes. It also defines two phases of PG change in OA: an early predominantly degenerate phase I followed by a net reparative phase II accompanied by net loss of these molecules. Find the latest version: https://jci.me/116113/pdf Studies of the Articular Cartilage Proteoglycan Aggrecan in Health and Osteoarthritis Evidence for Molecular Heterogeneity and Extensive Molecular Changes in Disease Geihan Rizkalla, * Agnes Reiner, * Earl Bogoch,t and A.
    [Show full text]